Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?
F Gohar, C Kessel, M Lavric, D Holzinger… - Arthritis research & …, 2016 - Springer
Background Diagnosing systemic juvenile idiopathic arthritis (SJIA) can be extremely
challenging if typical arthritis is lacking. A variety of biomarkers have been described for the …
challenging if typical arthritis is lacking. A variety of biomarkers have been described for the …
Fibromyalgia interferes with disease activity and biological therapy response in inflammatory rheumatic diseases
I Coskun Benlidayi - Rheumatology International, 2020 - Springer
Fibromyalgia is one of the numerous comorbidities that may accompany inflammatory
rheumatic diseases. Concomitant fibromyalgia in inflammatory rheumatic conditions can …
rheumatic diseases. Concomitant fibromyalgia in inflammatory rheumatic conditions can …
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity
JL Karnell, M Albulescu, S Drabic, L Wang… - Science translational …, 2019 - science.org
The CD40/CD40L axis plays a central role in the generation of humoral immune responses
and is an attractive target for treating autoimmune diseases in the clinic. Here, we report the …
and is an attractive target for treating autoimmune diseases in the clinic. Here, we report the …
Phase 1b study of the safety, pharmacokinetics, and disease-related outcomes of the matrix metalloproteinase-9 inhibitor andecaliximab in patients with rheumatoid …
DL Gossage, B Cieslarová, S Ap, H Zheng, Y Xin… - Clinical …, 2018 - Elsevier
Abstract Purpose Andecaliximab (GS-5745) is a highly selective monoclonal antibody
against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated in the …
against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated in the …
The building blocks of successful translation of proteomics to the clinic
Highlights•Many omics-based tests are proposed in the literature but very few make it to the
clinic.•First two multiplexed tests using selective reaction monitoring (SRM-MS) mass …
clinic.•First two multiplexed tests using selective reaction monitoring (SRM-MS) mass …
Synovial fluid proteomics in the pursuit of arthritis mediators: an evolving field of novel biomarker discovery
SM Mahendran, K Oikonomopoulou… - Critical Reviews in …, 2017 - Taylor & Francis
Synovial fluid (SF) is a protein-rich fluid produced into the joint cavity by cells of the synovial
membrane. Due to its direct contact with articular cartilage, surfaces of the bone, and the …
membrane. Due to its direct contact with articular cartilage, surfaces of the bone, and the …
Autoantibody discovery, assay development and adoption: death valley, the sea of survival and beyond
Dating to the discovery of the Lupus Erythematosus (LE) cell in 1948, there has been a
dramatic growth in the discovery of unique autoantibodies and their cognate targets, all of …
dramatic growth in the discovery of unique autoantibodies and their cognate targets, all of …
Pathways of impending disease flare in African-American systemic lupus erythematosus patients
ME Munroe, ES Vista, JT Merrill, JM Guthridge… - Journal of …, 2017 - Elsevier
Immune dysregulation in systemic lupus erythematosus (SLE) contributes to increased
disease activity. African-American (AA) SLE patients have an increased prevalence of …
disease activity. African-American (AA) SLE patients have an increased prevalence of …
Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis
AA Razmjou, J Brook, D Elashoff, G Kaeley, S Choi… - BMC rheumatology, 2020 - Springer
Background Musculoskeletal ultrasound (MSUS) and the multi-biomarker disease activity
(MBDA) score are outcome measures that may aid in the management of rheumatoid …
(MBDA) score are outcome measures that may aid in the management of rheumatoid …
Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic …
M Osiri, J Wongpiyabovorn, Y Sattayasomboon… - Clinical …, 2016 - Springer
The objective of this study was to compare the effects of treatment by combined conventional
disease-modifying antirheumatic drugs (cDMARDs) or biologics on cytokines, disease …
disease-modifying antirheumatic drugs (cDMARDs) or biologics on cytokines, disease …